Scientists identified vulnerable site on multiple coronaviruses
- Details
- Category: Research
The COVID-causing virus SARS-CoV-2 harbors a vulnerable site at the base of its spike protein that is found also on closely related coronaviruses, according to a new study from Scripps Research. The discovery, published in Science Translational Medicine, could inform the design of broad-acting vaccines and antibody therapies capable of stopping future coronavirus pandemics.
Suppressing the spread of tumors
- Details
- Category: Research
Why some patients develop metastases and others do not is largely unclear. Researchers around ISTA professor Daria Siekhaus are now contributing to a better understanding of the process in certain types of cancer. They took a close look at the role of a protein called MFSD1 - the mammalian relative of a protein they had previously identified as affecting cell migration in fruit flies.
With personalized medicine, a shelved cancer drug could get another shot
- Details
- Category: Research
A study by Virginia Commonwealth University Massey Cancer Center researchers published in today's print edition of Molecular Cancer Therapeutics shows that triplatin is effective against triple negative breast cancer, which is the most aggressive form of breast cancer and has few targeted therapies.
Computer predicted life saving benefit of Baricitinib for ventilated COVID patients
- Details
- Category: Research
Critically ill COVID-19 patients on a mechanical ventilator or extracorporeal membrane oxygenation (ECMO) lived more often when randomized to receive baricitinib. Doctors call this drug 'bari,' and receiving the pill once a day for up to 14 days yielded one of the largest a survival advantages seen yet in the COVID pandemic, according to a study published in The Lancet Respiratory Medicine.
Three exposures to spike protein allow people to develop broad antibody immunity - also against Omicron
- Details
- Category: Research
Scientists from Ludwig-Maximilians-Universitaet (LMU) in Munich, Helmholtz Munich, and Technical University of Munich have shown that the immune system is capable of neutralizing even Omicron after a total of three exposures to the viral spike protein.
Since the beginning of the COVID-19 pandemic, SARS-CoV-2 has continued to evolve, with new variants of concern (VoCs) spreading rapidly.
Study finds COVID-19 less severe in fully vaccinated
- Details
- Category: Research
The clinical and imaging characteristics of COVID-19 breakthrough infections in fully vaccinated patients tend to be milder than those of partially vaccinated or unvaccinated patients, according to a new multicenter study published in the journal Radiology.
The number of confirmed COVID-19 cases worldwide now exceeds 270 million with an overall mortality rate of approximately 2%.
The key to a powerful antibiotic's formation now clear
- Details
- Category: Research
A powerful class of antibiotics called carbapenems can circumvent antibiotic resistance thanks to a particular chain of atoms in their structure. Now, a team of researchers from Penn State and Johns Hopkins University have imaged an enzyme involved in the creation of this chain to better understand how it forms - and perhaps replicate the process to improve future antibiotics. A paper describing the process appears in the journal Nature.
More Pharma News ...
- Compound in the herb rosemary may be useful against COVID-19 and other inflammatory diseases
- Current COVID-19 vaccines induce robust cellular immunity against Omicron variant
- Parental vaccination against coronavirus offers substantial protection to children as well
- Delta variant, waning immunity reduced Pfizer vaccine's effectiveness against household transmission
- New study suggests two paths toward ‘super immunity’ to COVID-19
- The cellular response that protects pigs from COVID-19
- An estimated 1.2 million people died in 2019 from antibiotic-resistant bacterial infections